Compare · APGE vs MRNA
APGE vs MRNA
Side-by-side comparison of Apogee Therapeutics Inc. (APGE) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APGE and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $24.53B, about 2.4x APGE ($10.10B).
- Over the past year, APGE is up 240.9% and MRNA is up 97.7% - APGE leads by 143.2 points.
- APGE has been more active in the news (18 items in the past 4 weeks vs 11 for MRNA).
- MRNA has more recent analyst coverage (25 ratings vs 19 for APGE).
- Company
- Apogee Therapeutics Inc.
- Moderna Inc.
- Price
- $134.00-0.05%
- $61.80-2.14%
- Market cap
- $10.10B
- $24.53B
- 1M return
- +57.30%
- +11.57%
- 1Y return
- +240.88%
- +97.70%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- 2018
- News (4w)
- 18
- 11
- Recent ratings
- 19
- 25
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest APGE
- Chief Medical Officer Dambkowski Carl gifted 8,000 shares, decreasing direct ownership by 4% to 169,873 units (SEC Form 4)
- SEC Form DEFM14A filed by Apogee Therapeutics Inc.
- Chief Executive Officer Henderson Michael Thomas sold $2,672,600 worth of shares (20,000 units at $133.63) as part of a pre-agreed trading plan and gifted 75,046 shares, decreasing direct ownership by 9% to 920,941 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.
- Chief Medical Officer Dambkowski Carl sold $730,070 worth of shares (5,500 units at $132.74) as part of a pre-agreed trading plan and exercised 4,125 shares at a strike of $22.86, decreasing direct ownership by 0.77% to 177,873 units (SEC Form 4)
- SEC Form PREM14A filed by Apogee Therapeutics Inc.
- SEC Form DEFA14A filed by Apogee Therapeutics Inc.
- Chief Medical Officer Dambkowski Carl sold $3,500,640 worth of shares (26,400 units at $132.60) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 179,248 units (SEC Form 4)
Latest MRNA
- President Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $3,605,514 worth of shares (53,336 units at $67.60) as part of a pre-agreed trading plan (SEC Form 4)
- Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Moderna Appoints Michael McDonnell to Board of Directors
- SEC Form 4 filed by Chief Commercial Officer Banque Soria Ester
- Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 1% to 66,436 units (SEC Form 4) to satisfy withholding tax
- SEC Form 3 filed by new insider Banque Soria Ester